Physician profile
Michael L Bloom
NPI 1306834171
$8,366.91
in general payments reported to CMS, 2019-2025
31 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $552 · 2021: $1,022 · 2022: $865 · 2023: $1,157 · 2024: $2,111 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,748.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,807.67 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,476.90 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Phathom Pharmaceuticals, INC. | $701.13 | 2024 | Voquezna |
| Genzyme Corporation | $597.22 | 2022-2025 | |
| Qol Medical, LLC | $583.94 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $429.12 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $351.43 | 2019-2022 | |
| Ardelyx, INC. | $298.60 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $293.71 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $209.60 | 2019-2025 | |
| Celgene Corporation | $208.37 | 2021-2023 | |
| Madrigal Pharmaceuticals | $148.86 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $135.56 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $122.61 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $117.36 | 2024-2025 | Zenpep |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $103.73 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $98.58 | 2021 | |
| Boston Scientific Corporation | $87.70 | 2024 | Watchman Flx |
| American Regent | $84.68 | 2024 | Injectafer |
| Braintree Laboratories, INC. | $76.06 | 2023-2025 | Suflave, Sutab |
| Celltrion USA INC. | $74.15 | 2024-2025 | Vegzelma |
| Allergan, INC. | $72.40 | 2019-2020 | |
| Redhill Biopharma INC. | $69.34 | 2020-2024 | Talicia, Aemcolo |
| Janssen Biotech, INC. | $66.31 | 2021-2024 | Stelara |
| Novo Nordisk INC | $43.52 | 2022-2025 | Wegovy |
| Intra-Sana Laboratories | $23.13 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ucb, INC. | $19.08 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.13 | 2023 | Givlaari |
| Shire North American Group INC | $18.11 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.49 | 2023 | |
| Evoke Pharma, INC. | $14.42 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.